ZGZufeng Guo

Zufeng Guo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Zufeng Guo has a total of 125 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Structure-guided design and optimization of 3-amino-pyrazine-2-oxadiazole derivatives as novel FGFR2 inhibitors

    by Wei Zhang, Enqin Yang, Jia Zheng, Xinning Li, Chen Su, Yuting Fu, Ling Jiang, Yi He, Yongjun Dang, Linfeng Li, et al.

  • High‐throughput identification of carboxylate‐free ligands for the E3 ligase Kelch domain‐containing protein 2

    by Yao Chen, Ruichen Gao, Jiajia Li, Ruijie Li, Xinyu Wang, Xi Tang, Xing Wang, Yue Wei, Linfeng Li, Yuying Ma, et al.

    Expanding the repertoire of usable E3 ubiquitin ligases remains a critical challenge in the field of targeted protein degradation. For the emerging E3 ligase Kelch domain‐containing protein 2 (KLHDC2), currently reported ligands have a carboxylate moiety in common that mimics the natural degron but compromises cellular permeability. Here we report the discovery of carboxylate‐free ligands for KLHDC2 through high‐throughput screening and cellular functional evaluation. A fluorescence polarization‐based screening assay identified NL1 as a micromolar KLHDC2 binder, which was confirmed by orthogonal biophysical methods. Although the structure–activity study did not improve affinity, a degron reporter assay demonstrated measurable cellular target engagement. Encouraged by these results, an expanded screen further identified NL2 as a neutral ligand with improved cellular activity. Computational analysis suggests that NL2 adopts a distinct binding mode, in which the conformational flexibility of two loops of KLHDC2 enables accommodation of its aromatic scaffold, while hydrophobic and π‐driven interactions compensate for the canonical ionic contacts of other carboxylate‐containing ligands. This work demonstrates that KLHDC2 can accommodate non‐carboxylate scaffolds and expands the chemical space for developing KLHDC2‐based targeted protein degradation strategies.

  • Structure-Guided Discovery of Novel Dual-Site FEM1B Ligands and Assessment of Their Use in Targeted Protein Degradation

    by Lingbo Xu, Ruyi Huang, Yuying Ma, Li Yang, Yueying Li, Chengping He, Zhenhao Zhang, Yang Teng, Wei Li, Zan Chen, et al.

    Targeted protein degradation (TPD) represents a promising approach for eliminating disease-causing proteins beyond traditional inhibition. However, the reliance on a limited number of E3 ligases remains a major bottleneck. FEM1B, an E3 ligase substrate receptor with multiple substrate-recognition modes, represents an attractive but underexplored TPD platform. In this study, through a structure-guided approach exploiting the spatial proximity between a druggable C-degron-binding pocket and a second binding site containing a reactive cysteine, we developed FL47, a dual-site ligand that combines extensive noncovalent interactions with targeted covalent engagement. FL47 exhibits submicromolar affinity, robust cellular target engagement, and markedly reduced cytotoxicity relative to previously reported covalent recruiters. We further applied FL47 in the development of FEM1B-based PROTACs and incorporated a chemical endocytic prodrug strategy that markedly enhanced degradation activity. This work introduces a novel dual-site binding strategy for E3 ligase ligand discovery and broadens the potential toolbox for TPD applications.

  • Open Access

    Reduced Maintenance DNA Methylation Thresholds Enable Sensitive Reporter Assays for UHRF1 and DNMT1 Inhibition

    by Cuicui Xia, Ying Cui, Jiongliang Wang, Wenjing Bai, Danyang Wang, Yao Chen, Huahui Guo, Liangyi Zong, Bing Qin, Xintong Cai, et al.

    Aberrant DNA methylation and consequent silencing of tumor suppressor gene (TSGs) are maintained by UHRF1‐mediated recruitment of DNMT1, making the UHRF1‐DNMT1 axis as an attractive target for hypomethylating agents (HMAs). However, fully reversing DNA methylation abnormalities requires lowering DNMT1 below a deep threshold, posing major drug discovery challenges. Here, we demonstrated that a similarly stringent threshold applied to UHRF1 in maintaining hypermethylated TSG suppression. Genetically reducing redundancy in DNMT1 or UHRF1 markedly lowered these thresholds, sensitizing cells to their inhibition. These findings were translated into engineered recombinant reporter systems tied to endogenous hypermethylated promoters in hypomorphic cells, substantially improving sensitivity and dynamic range for monitoring HMA‐induced TSG reactivation. Pilot high‐throughput screening validated assay robustness and specificity for DNMT1 and UHRF1 inhibitors. Additionally, these platforms enabled optimization of timing and combination strategies pairing DNMT1/UHRF1 inhibitors with other epigenetic agents to maximize TSG re‐expression. Our study supports the concept of maintenance methylation thresholds and provides versatile tools for discovering novel HMAs and designing epigenetic combination therapies.


  • Open Access

    Systematic Optimization of Proteolysis-Targeting Chimeras for PIN1 Enables Selective Degradation and Antitumor Activity In Vivo

    by Yuying Ma, Yang Teng, Jinjin Liu, Yuke Deng, Lingbo Xu, Ruichen Gao, Tingyu Peng, Wei Li, Yue Wei, Linfeng Li, et al.

    Background: The peptidyl–prolyl cis–trans isomerase PIN1 regulates multiple oncogenic and tumor-suppressive pathways and is frequently overexpressed in human cancers. Although pharmacological inhibition of PIN1 has shown antitumor potential, existing PIN1-targeting degraders lack systematic structure–activity relationship (SAR) analyses and display inconsistent cellular efficacy, leaving the therapeutic relevance of PIN1 degradation unclear. Methods: Two series of PIN1-targeting PROTACs were designed using the covalent inhibitor sulfopin as the PIN1 binder and ligands for either cereblon (CRBN) or von Hippel–Lindau (VHL). Systematic SAR studies focused on linker structure and jointing atom composition. PIN1 degradation was assessed by Western blotting in multiple cancer cell lines, and further investigated through a series of computational and mechanistic experiments. Antitumor efficacy and safety were evaluated in an MCF-7 xenograft mouse model with preliminary pharmacokinetic analysis. Results: SAR analysis revealed that short, linear linkers and reduced hydrogen bond donor content markedly enhanced PIN1 degradation, whereas VHL-recruiting PROTACs showed inferior cellular activity. These studies identified PC2, a CRBN-recruiting PROTAC, as a lead compound. PC2 selectively induced ubiquitin–proteasome-dependent PIN1 degradation with minimal global proteomic or transcriptomic perturbation. Despite modest antiproliferative effects in vitro, PC2 significantly suppressed tumor growth in vivo without observable toxicity and achieved effective intratumoral PIN1 degradation. Conclusions: This study defines SAR-guided design principles for PIN1-targeting PROTACs and demonstrates that selective PIN1 degradation can produce robust antitumor activity in vivo. PC2 represents the first PIN1 degrader validated in animal models and supports targeted PIN1 degradation as a viable anticancer strategy.


  • Open Access

    High-throughput ligand discovery in living cells using the cellular protein stability enhancement assay

    by Yue Wei, Yunyun Gao, Ruijie Li, Yao Chen, Wenjing Bai, Peirui Zhao, Junchi Hu, Linfeng Li, Xing Wang, Guobing Yin, et al.

  • Open Access

    Rapavir, a novel inhibitor of sodium taurocholate cotransporting polypeptide, potently blocks hepatitis B virus entry

    by Jia He, Haibo Yu, Kunling Song, Ailong Huang, Yongjun Dang, Juan Chen, Zufeng Guo


  • Open Access

    Circulating Tumor Microenvironment in Metastasis

    by Rui Tang, Shujuan Luo, Hui Liu, Yan Sun, Manran Liu, Lu Li, Haoyu Ren, Martin K. Angele, Nikolaus Börner, Keda Yu, et al.

    Activation of invasion and metastasis is a central hallmark of cancer, contributing to the primary cause of death for patients with cancer. In the multistep metastatic process, cancer cells must infiltrate the circulation, survive, arrest at capillary beds, extravasate, and form metastatic clones in distant organs. However, only a small proportion of circulating tumor cells (CTC) successfully form metastases, with transit of CTCs in the circulation being the rate-limiting step. The fate of CTCs is influenced by the circulating tumor microenvironment (cTME), which encompasses factors affecting their biological behaviors in the circulation. This liquid and flowing microenvironment differs significantly from the primary TME or the premetastatic niche. This review summarizes the latest advancements in identifying the biophysical cues, key components, and biological roles of the cTME, highlighting the network among biophysical attributes, blood cells, and nonblood factors in cancer metastasis. In addition to the potential of the cTME as a therapeutic target for inhibiting metastasis, the cTME could also represent as a biomarker for predicting patient outcomes and developing strategies for treating cancer.


  • Open Access

    Epoxy metabolites of linoleic acid promote the development of breast cancer via orchestrating PLEC/NFκB1/CXCL9-mediated tumor growth and metastasis

    by Kai-Di Ni, Xian Fu, Ying Luo, Xin He, Hou-Hua Yin, Dong-Ping Mo, Jing-Xian Wu, Ming-Jun Wu, Xiao Zheng, Ya-Nan Liu, et al.

    Breast cancer (BC) is a common malignant tumor in women and requires a comprehensive understanding of its pathogenesis for the development of new therapeutic strategies. Polyunsaturated fatty acids (PUFAs) metabolism-driven inflammation is a causative factor in cancer development. However, the function of PUFAs′ metabolism in BC remains largely unknown. Here we report the role and underlying mechanism of epoxyoctadecenoic acids (EpOMEs), the metabolites of linoleic acid mediated by cytochrome P450 (CYP) monooxygenases, in promoting the development of BC, particularly triple-negative BC (TNBC). A metabolomics study identified that EpOMEs were significantly increased in the plasma of BC patients and MMTV-PyMT mice, which accounted for the upregulation of CYP2J2 in BC tumor tissues and tumor cells. Decreased EpOMEs by treatment of CYP monooxygenase inhibitors significantly alleviated tumor development in MMTV-PyMT mice. Treatment with EpOMEs and overexpression of CYP2J2 to increase EpOMEs in TNBC cells significantly promoted cellular proliferation, migration, tumor growth, and metastasis. Whereas knockdown of CYP2J2 to decrease EpOMEs inhibited tumorigenesis and lung metastasis of TNBC, which was reversed by EpOME administration. Transcriptomics and proteomics analyses revealed CXCL9 and PLEC were critical for EpOME-mediated promotion of TNBC. Knockdown of CXCL9 and PLEC inhibited TNBC progression and EpOME-mediated promotion of TNBC. Both overexpression of CYP2J2 and EpOME treatment upregulate PLEC, while PLEC upregulates NFκB1, which is a transcription regulator of CXCL9. This study extends the understanding of the function of PUFAs metabolism in BC development, providing potential therapeutic targets and dietary guidelines for patients with TNBC and other BCs.


  • Design, Synthesis, and Biological Evaluation of 3-Amino-pyrazine-2-carboxamide Derivatives as Novel FGFR Inhibitors

    by Jia Zheng, Wei Zhang, Dan Ni, Shuang Zhao, Yi He, Junchi Hu, Linfeng Li, Yongjun Dang, Zufeng Guo, Shenyou Nie

    FGFR has been considered a crucial oncogenic driver and promising target for cancer therapy. Herein, we reported the design and synthesis of 3-amino-N-(3,5-dihydroxyphenyl)-6-methylpyrazine-2-carboxamide derivatives as novel FGFR inhibitors. SAR exploration led to the identification of 18i as a pan-FGFR inhibitor with favorable in vitro activity against FGFR1-4. Moreover, 18i blocked the activation of FGFR and downstream signaling pathways at the submicromolar level and exhibited potent antitumor activity in multiple cancer cell lines with FGFR abnormalities. Molecular docking was performed to investigate the possible binding modes of 18i within the binding site of FGFR2. These results suggest that compound 18i is a promising candidate for further drug discovery.